Glenmark signs licensing agreement with Lotus International to commercialize Ryaltris
Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lous Pharmaceutical, Glenmark will be responsible for the manufacturing and supply of Ryaltris. On the other hand, Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.
New Delhi: Glenmark Pharmaceuticals on Thursday said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Ltd for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong, and Vietnam.
Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lous Pharmaceutical, Glenmark will be responsible for the manufacturing and supply of Ryaltris. On the other hand, Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.
Glenmark will receive and upfront payment as well as regulatory and sale-based milestone payments from Lotus, it added.
Lotus CEO, Petar Vazharov said, "The partnership not only strengthens the competitiveness of our overall product portfolio but also accelerates our expansion in key SEA countries".
He further said this is also the first brand product to be included in Lotus' respiratory portfolio with strong clinical data and IP protection.
Ryaltris, developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis in adults and pediatric patients, 12 years of age and older.
Glenmark said it has also entered into commercial agreements with several partners around the world including Menarini for the commercialization of Ryaltris in select EU markets with Bausch Health in Canada( where is under review by Health Canada), with Grand Pharma in China, and with Yuhan Corporation in South Korea for commercialization of the nasal spray.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.